FeesSafety
Pluang+

Holcim reports strong Q3 2026 with double-digit growth in sales and recurring EBIT, momentum expected to continue.

Company Fundamentals
23 Oct 2026
Seeking Alpha
View Source
Bullish
Holcim reports strong Q3 2026 with double-digit growth in sales and recurring EBIT, momentum expected to continue.

Holcim announced a robust performance for the first nine months of 2026, with organic net sales growth of 5.2% and an 11.8% increase in recurring EBIT. The third quarter marked a new phase of double-digit growth in Swiss francs for both net sales and recurring EBIT. The company expects this positive momentum to continue in the coming quarters, signaling strong operational performance and growth prospects.

Holcim AG Q3 2026 sales and trading call provides context for basic materials sector activity. For readers following this sector, here is Pluang's market snapshot as of Oct 23, 2026 18:12 WIB: Of 83 priced basic materials US stocks, 33 rose and 45 fell today. Notable movers include AMRZ at USD 39.86 (+1.06%), EQX at USD 10.25 (-1.06%), and CLMT at USD 49.84 (+1.05%).

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
19 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App